PAVM: PAVmed Inc.
Dilution Risk Score 89/100

PAVmed Inc. (PAVM) carries a Critical dilution risk score of 89 out of 100 based on DilutionWatch's real-time analysis of SEC EDGAR filings. Contributing factors include convertible securities representing 803% of current share count.

Why PAVM Has a Critical Dilution Risk Score

DilutionWatch scores every ticker on a 0–100 scale by analyzing five components: cash runway, warrant overhang, convertible securities, active shelf/ATM capacity, and historical filing patterns. A score of 89 means PAVM is in the highest-risk category across multiple dimensions simultaneously.

• Cash runway: Estimated at 3.4 months — limited, increasing pressure to raise additional capital in the near term
• Warrant overhang: Outstanding warrants represent 82% of current shares outstanding — significant potential dilution if exercised at or near current prices
• Convertible securities: Convertible notes/instruments represent 803% of current shares — creating extreme dilution risk if converted
• Filing pattern: 5 dilutive filings in the past 12 months (last: 2025-04-21), indicating a pattern of repeat capital raises

Recent SEC Filing History for PAVM

The following dilutive filings have been detected for PAVM in the past 12 months via DilutionWatch's real-time EDGAR monitoring:

How to Monitor PAVM for Dilution Alerts

DilutionWatch polls SEC EDGAR every 60 seconds. When PAVmed Inc. files an S-3, 424B, 8-K financing disclosure, or any of 25 tracked filing types, you receive an alert before the stock reprices. This is the same monitoring capability that institutional traders use — available to retail investors through DilutionWatch's free tier.

Additional Dilution Risk Analysis for PAVM

Historical Patterns of Critical Risk Levels for Retail Investors

A dilution risk score of 89/100 places PAVM in the critical zone, typically signaling significant exposure for retail shareholders. Historically, companies with scores above 85 have often experienced rapid share price declines post-dilution events, particularly when accompanied by large warrant issuances or shelf registrations. Retail investors should expect heightened volatility and potential losses if the company proceeds with additional equity offerings without strong underlying fundamentals. While some critical-risk stocks recover, the pattern suggests that retail investors are more likely to see their positions eroded unless there is a clear plan for capital efficiency and growth.

Key SEC Filings to Monitor

Investors should closely monitor the following filings on EDGAR for early warning signs:

• S-3 Registration Statements – Indicate potential large-scale equity offerings, often used for shelf registrations.
• 8-K Reports – Provide real-time updates on material events like new equity issuances or warrant exercises.
• 424B5 Filings – Used to announce PIPE deals or rights offerings, often tied to dilution.

These filings are critical for tracking the company’s capital-raising activities and can reveal whether PAVM is planning further equity dilution that could impact shareholder value.

DilutionScore vs. Sector Averages

PAVM’s score of 89 significantly exceeds the sector average, which typically ranges from 30–50 for mid-cap healthcare and biotech companies. This means PAVM is facing above-average dilution pressure, especially when compared to peers in similar market segments. shows that many companies with comparable market caps are managing their capital more efficiently, resulting in lower risk scores. The outlier status suggests investors should closely evaluate whether the company’s strategic direction justifies the elevated dilution risk.

Next Steps for Investors Monitoring PAVM

For investors tracking this stock, immediate actions include:

• Regularly checking Warrant Tracker to monitor any new warrant issuances or exercises.
• Using the DilutionWatch to compare PAVM’s risk metrics with other biotech stocks.
• Monitoring for signs of shelf registration filings via Shelf & ATM Monitor.